MicroTransponder has received $65m in a Series F financing round, which aims to enhance its stroke care offerings with the Vivistim Paired vagus nerve stimulation (VNS) System. The financing round was ...

After a stroke, gamma oscillations disappear, and parvalbumin neurons lose their connections. Gamma oscillations are like the ...

A new study has discovered what researchers say is the first drug to fully reproduce the effects of physical stroke ...

There's newfound hope for stroke patients in recovery, with what researchers believe is the very first drug that can ...

Patients come to VRC after their initial, and typically emergent, hospitalization for a stroke. At VRC a multidisciplinary team comprised of doctors, nurses, physical therapists, speech therapists, ...

An imbalance in ligands, which are molecules produced by the body and the gut microbiota, can affect a key receptor protein ...

lovelyday12 – stock.adobe.com “The combination therapy is safe and efficacious ... which can restrict blood flow and lead to heart attack or stroke. High cholesterol is a major risk ...

Manufactured by MicroTransponder®, Inc. and FDA-approved as a Breakthrough Device, Vivistim is an implantable device that helps stroke survivors live fuller lives by pairing vagus nerve stimulation ...

In a preclinical study, rodents treated with uric acid showed improved long-term outcomes after acute ischemic stroke. The findings suggest that the treatment may work as an add-on therapy to standard ...